GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 3.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,228,473 shares of the company’s stock after selling 73,007 shares during the period. American Century Companies Inc. owned about 0.49% of GE HealthCare Technologies worth $174,222,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Runnymede Capital Advisors Inc. acquired a new position in shares of GE HealthCare Technologies in the fourth quarter worth about $28,000. Continuum Advisory LLC raised its position in shares of GE HealthCare Technologies by 101.8% in the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after acquiring an additional 168 shares during the period. Bank of Jackson Hole Trust acquired a new position in shares of GE HealthCare Technologies in the fourth quarter worth about $32,000. OFI Invest Asset Management acquired a new position in shares of GE HealthCare Technologies in the fourth quarter worth about $34,000. Finally, Flagship Wealth Advisors LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter worth about $34,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on GEHC. Citigroup upped their price objective on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. The Goldman Sachs Group upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $85.00 to $100.00 in a research report on Tuesday, March 11th. Wells Fargo & Company upped their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their price target for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and an average target price of $98.75.

GE HealthCare Technologies Stock Down 0.4 %

Shares of NASDAQ GEHC opened at $81.49 on Friday. GE HealthCare Technologies Inc. has a 12-month low of $74.51 and a 12-month high of $94.80. The stock has a market cap of $37.27 billion, a PE ratio of 18.82, a P/E/G ratio of 3.19 and a beta of 1.13. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88. The company has a 50-day moving average of $87.02 and a 200 day moving average of $86.03.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The company had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. As a group, sell-side analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.